公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2019 | Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer | Park K; Bennouna J; Boyer M; Hida T; Hirsh V; Kato T; Lu S; Mok T; Nakagawa K; O'Byrne K; Paz-Ares L; Schuler M; Sibilot D.M; Tan E.-H; Tanaka H; Wu Y.-L; CHIH-HSIN YANG ; Zhang L; Zhou C; Märten A; Tang W; Yamamoto N. | Lung Cancer | 26 | 26 | |
2013 | Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: Results of a randomized phase iib/iii trial (lux-lung 1) | Hirsh V; Cadranel J; Cong X.J; Fairclough D; Finnern H.W; Lorence R.M; Miller V.A; Palmer M; CHIH-HSIN YANG | Journal of Thoracic Oncology | 65 | 59 | |
2013 | Symptom control and quality of life in lux-lung 3: A phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations | CHIH-HSIN YANG ; Hirsh V; Schuler M; Yamamoto N; O'Byrne K.J; Mok T.S.K; Zazulina V; Shahidi M; Lungershausen J; Massey D; Palmer M; Sequist L.V. | Journal of Clinical Oncology | 295 | 242 |